- Joined
- Dec 17, 2007
- Messages
- 3,719
- Reaction score
- 5,243
We treat according to DAHANCA, but do not use nimorazole.For those who treat using the DAHANCA data, are you doing this also:
"All patients, except those with glottic cancers, also received the hypoxic radiosensitiser nimorazole."
I presume it's based on this?

A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85 - PubMed
Nimorazole significantly improves the effect of radiotherapeutic management of supraglottic and pharynx tumors and can be given without major side-effects.
